"alpha-Synuclein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A synuclein that is a major component of LEWY BODIES that plays a role in neurodegeneration and neuroprotection.
| Descriptor ID |
D051844
|
| MeSH Number(s) |
D12.776.631.860.500 D12.776.637.500
|
| Concept/Terms |
alpha-Synuclein- alpha-Synuclein
- alpha Synuclein
- Non-AB Component of AD Amyloid Protein
- Non AB Component of AD Amyloid Protein
|
Below are MeSH descriptors whose meaning is more general than "alpha-Synuclein".
Below are MeSH descriptors whose meaning is more specific than "alpha-Synuclein".
This graph shows the total number of publications written about "alpha-Synuclein" by people in this website by year, and whether "alpha-Synuclein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 2 | 3 |
| 2008 | 0 | 1 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 1 | 2 |
| 2011 | 3 | 0 | 3 |
| 2012 | 3 | 1 | 4 |
| 2013 | 2 | 2 | 4 |
| 2014 | 3 | 1 | 4 |
| 2015 | 6 | 1 | 7 |
| 2016 | 6 | 3 | 9 |
| 2017 | 6 | 4 | 10 |
| 2018 | 2 | 5 | 7 |
| 2019 | 3 | 1 | 4 |
| 2020 | 4 | 5 | 9 |
| 2021 | 1 | 6 | 7 |
| 2022 | 2 | 0 | 2 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "alpha-Synuclein" by people in Profiles.
-
Mixed pathology as a rule, not exception: Time to reconsider disease nosology. Handb Clin Neurol. 2023; 192:57-71.
-
A prebiotic diet modulates microglial states and motor deficits in a-synuclein overexpressing mice. Elife. 2022 11 08; 11.
-
Treadmill exercise reduces a-synuclein spreading via PPARa. Cell Rep. 2022 07 12; 40(2):111058.
-
A historical review of multiple system atrophy with a critical appraisal of cellular and animal models. J Neural Transm (Vienna). 2021 10; 128(10):1507-1527.
-
Selective targeting of the TLR2/MyD88/NF-?B pathway reduces a-synuclein spreading in vitro and in vivo. Nat Commun. 2021 09 10; 12(1):5382.
-
A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation. Clin Pharmacol Ther. 2021 08; 110(2):508-518.
-
Gut and brain profiles that resemble pre-motor and early-stage Parkinson's disease in methamphetamine self-administering rats. Drug Alcohol Depend. 2021 08 01; 225:108746.
-
Proteomic Profiling of the Substantia Nigra to Identify Determinants of Lewy Body Pathology and Dopaminergic Neuronal Loss. J Proteome Res. 2021 05 07; 20(5):2266-2282.
-
GDNF signaling in subjects with minimal motor deficits and Parkinson's disease. Neurobiol Dis. 2021 06; 153:105298.
-
Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nat Genet. 2021 03; 53(3):294-303.